Goals of Planned National Pain Research Consortium Outlined

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

WASHINGTON--An announcement by NIH director Harold E. Varmus, MD, of a plan to form a national pain research consortium came as a complete, but pleasant surprise to the American Pain Society, Martin Grabois, MD, president of the Society, said in an interview with Oncology News International.

WASHINGTON--An announcement by NIH director Harold E. Varmus, MD, ofa plan to form a national pain research consortium came as a complete,but pleasant surprise to the American Pain Society, Martin Grabois, MD,president of the Society, said in an interview with Oncology News International.

In his keynote address at the Society's Annual Scientific Meeting, Dr.Varmus said that the consortium will comprise representatives from variousbranches of the NIH, including, but not limited to, the National Instituteof Neurological Diseases and Stroke, National Cancer Institute, NationalInstitute on Aging, and National Institute of Arthritis and Musculoskeletaland Skin Diseases.

Dr. Varmus said that the consortium would serve as a centralized clearinghousefor projects and information on pain, help to publicize the aims and accomplishmentsof pain specialists, and foster collaboration and dialogue among scientists,pain societies, advocacy groups, and other members of the pain community.

Proposed Functions of the Planned NIH Pain Research Consortium

Dr. Grabois, professor and chairman of physical medicine and rehabilitation,Baylor College of Medicine, said that the Society was very enthused bythe announcement. If the consortium carries out the goals and functionsDr. Varmus described in his talk (see table above), he said, "I thinkthat would go a long way toward upgrading pain research conducted at NIHor with NIH support." However, he noted that Dr. Varmus included notime frame for the formation of the consortium. "We would like tosee how the plan is implemented and take a look a year later to see howwell the consortium's stated goals have been met."

Charles S. Cleeland, PhD, outgoing president of the Society, said thatthe consortium would bring a "needed level of coordination of painresearch at the NIH." He added that he hoped the consortium "willlook for advice and counsel from the community of patients who suffer painand the professionals who try to help these patients."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content